Related Experiment Videos
Hypertension and new antihypertensive drugs: clinical perspectives
Insights
Hypertension treatment has shifted focus from high blood pressure to preventing atheroma complications. New drugs must minimize toxicity and side effects while potentially improving ischemic heart disease outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Hypertension drug therapy has evolved over 30 years, changing the primary clinical challenge.
- High blood pressure-related cardiovascular pathology is no longer the main concern; atheroma complications, especially coronary artery disease, are now the leading cause of death.
Purpose of the Study:
- To identify new antihypertensive drug criteria based on current clinical challenges.
- To explore promising therapeutic approaches for mild hypertension with small benefit margins.
Main Methods:
- Review of current hypertension treatment landscape and drug therapy outcomes.
- Analysis of the main causes of mortality in hypertensive patients.
- Evaluation of potential new drug classes and their mechanisms of action.
Main Results:
- Mild hypertension treatment offers modest benefits, necessitating drugs with minimal toxicity and side effects.
- New antihypertensive agents should ideally reduce morbidity and mortality from ischemic heart disease.
Conclusions:
- Future hypertension drug development must prioritize safety and efficacy in managing mild cases.
- Promising avenues include beta-adrenergic blockers, calcium entry blockers, ACE inhibitors, and prostanoid derivatives for their potential cardiovascular benefits.
Abstract:
The nature of the clinical problem posed by hypertension has been changed fundamentally by 30 years of successful drug therapy. Cardiovascular pathology directly related to the high pressure is no longer the main problem. Complications of atheroma, particularly in the coronary arteries, are the main cause of hypertension-related deaths. Most patients now starting treatment have mild hypertension and the benefits, although significant, are small (two deaths prevented per 1000 patient-years of treatment). These two considerations dictate that new drugs must have a very low incidence of toxicity, a low incidence of symptomatic side effects, and preferably, a favorable effect on morbidity and mortality from ischemic heart disease. Several possible approaches have promise: 1) reduction of ischemic heart disease mortality by beta-adrenergic blockade; 2) use of calcium entry blocking drugs, which may combine vasodilation with antiarrhythmic effects; 3) non-thiol-converting enzyme inhibitors, which may have a particularly low incidence of side effects; 4) prostanoid derivatives that may combine vasodilatation with an antiplatelet action.